eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2021-05-10 9 8 424 427 10.12691/ajmcr-9-8-10 AJMCR20219810 article Silfat Azam 1 Abdalla Khalil abdallak59@gmail.com 1 Ahmad Taha 2 Acute Medicine Department, Princess Royal University Hospital, KingĄ¯s college trust, London BR6 8ND, UK Radiology Department, Princess Royal University Hospital, KingĄ¯s College trust, London BR6 8ND, UK Since the COVID-19 pandemic has started in December 2019, millions of people have been infected all over the world and few vaccines have been invented recently. Extremely rare, Guillain-Barre Syndrome (GBS) was reported as a neurological complication after H1N1 flu vaccination. Currently, Pfizer and AstraZeneca vaccines are available to prevent infection with COVID-19. The first case of post-COVID-19 vaccine GBS has been detected in a secondary care hospital after vaccination with AstraZeneca. A 67-year-old man presented with an acute progressive ascending flaccid symmetrical motor neuropathy, and bilateral facial weakness which developed two weeks after receiving the first dose of AstraZeneca COVID-19 vaccine. His cerebrospinal fluid findings, nerve conduction result, and MRI brain result were all in favour of GBS diagnosis. The patientĄ¯s workup for all known infections associated with immune-mediated GBS was negative. http://pubs.sciepub.com/ajmcr/9/8/10/ajmcr-9-8-10.pdf COVID-19 infection COVID-19 vaccine Guillain-Barre Syndrome (GBS) Miller Fisher Syndrome (MFS)